Skip to content
Medical Health Aged Care

Novotech Releases Report on Current State of Triple-Negative Breast Cancer Clinical Trials

Novotech 3 mins read

Key biomarkers and cutting-edge treatments, such as PARP inhibitors and immunotherapy combinations, drive advancements in TNBC outcomes


SYDNEY--BUSINESS WIRE--

Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for Triple-Negative Breast Cancer (TNBC). The report highlights significant advancements in therapeutic strategies, regional clinical trial activity, and evolving biomarkers driving innovative TNBC treatments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113960593/en/

A Highly Aggressive Breast Cancer Subtype

TNBC, representing 10-15% of breast cancer cases worldwide, is characterized by the absence of key receptors (ER, PR, HER2), limiting the efficacy of targeted hormonal therapies. Despite advances, TNBC remains associated with poor survival rates, with metastatic cases exhibiting five-year survival of under 12%.

Global Clinical Trial Insights

From 2019 to 2024, over 1,500 clinical trials for TNBC were initiated globally, highlighting a robust commitment to improving patient outcomes. Key findings include:

  • Regional Leadership: North America led TNBC trials (39%), followed closely by Asia-Pacific (33%), Europe (21%), and ROW (7%). The United States accounted for 83% of North America’s trials, while China and Australia emerged as regional leaders in Asia-Pacific.
  • Biomarker-Driven Research: Novel biomarkers such as BRCA1/2 mutations, PD-L1 expression, and FGFR amplifications are increasingly targeted to drive precision therapies.
  • Trial Density & Recruitment: Asia-Pacific’s lower trial density and faster recruitment rates provide unique opportunities for TNBC-focused research, supported by a large and diverse patient pool.

Innovation in Therapeutics

TNBC drug development reflects a multi-stage pipeline, with 78 Phase I, 97 Phase II, and 12 Phase III trials underway. The evolution of therapeutic strategies includes:

  • Targeted Therapies: PARP inhibitors, immune checkpoint inhibitors (ICIs), and novel antibody-drug conjugates (ADCs) are transforming treatment paradigms.
  • Combination Approaches: Synergistic therapies combining immunotherapy, chemotherapy, and targeted agents are enhancing efficacy.

Significant Opportunity in Asia-Pacific

The Asia-Pacific region, with its genetic diversity and unmet clinical needs, remains a focal point for TNBC trials. Novotech’s presence in key Asia-Pacific markets provides a strategic advantage in accelerating clinical research for novel TNBC therapies.

About NovotechNovotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com


Contact details:

Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135

Media

More from this category

  • Medical Health Aged Care
  • 14/02/2025
  • 17:00
NIPPON EXPRESS HOLDINGS, INC.

NIPPON EXPRESS HOLDINGS Completes Procedure to Make Germany’s SH HoldCo Wholly-owned Subsidiary

TOKYO, Feb. 14, 2025 /Kyodo JBN/ -- - Completion of Acquisition (Subsidiarization) of SH HoldCo GmbH Shares - NIPPON EXPRESS HOLDINGS, INC. is pleased to announce that the agreement concluded on September 30, 2024, for the acquisition of entire shares in SH HoldCo GmbH, the parent company of the Germany-based Simon Hegele Group, was executed with effect from February 3, 2025 ("the Transaction"). NX Logo: https://kyodonewsprwire.jp/img/202502063911-O3-3GW0nv63 The founder, Dieter Hegele (left), and the President of NXHD, Satoshi Horikiri: https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202502063911/_prw_PI1fl_Q8fxy492.jpg Headquartered in Karlsruhe, Germany, Simon Hegele is a contract logistics provider founded in 1920 that specializes in providing logistics services for…

  • Medical Health Aged Care
  • 14/02/2025
  • 15:37
Dementia Australia

Last chance to join us for Canberra Memory Walk & Jog!

With only a few sleeps to go, walkers, joggers, runners and volunteers are gearing up to participate in the 2025 Canberra Memory Walk & Jog. More than 1000 people have already signed-up to take part – but there’s always room for more with online registrations still open, or sign-up on the day of the event. Dementia Australia CEO Professor Tanya Buchanan said it was fantastic to see Canberra locals throwing their support behind Memory Walk & Jog, all while getting active for their brain health. “We look forward to hosting Memory Walk & Jog on Sunday 23 February at Barrine…

  • Contains:
  • Medical Health Aged Care
  • 14/02/2025
  • 15:25
Dementia Australia

Tamworth shows their support for people impacted by dementia

Tamworth community members turned up in force last weekend, showing their support for people impacted by dementia whilst getting active to improve their brain health. Participating in the 2025 Memory Walk & Jog at Bicentennial Park, more than 95 people walked, ran and jogged to raise an impressive total of $6600. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the Tamworth community who turned out in such large numbers for the first time in support of people impacted by dementia,”…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.